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B
ACKGROUND: Acute myocardial infarction 
(AMI) is one of cardiovascular diseases with high 
morbidity and mortality rates. Novel biomarkers 
that can detect accurately acute coronary syndrome (ACS) 
at early stage, are necessary to improve current strategies 
and/or to identify subjects who are at risk. Fibrinogen 
and high-sensitivity C-reactive protein (hs-CRP) roles 
in inlammation process could be potential for ACS 
early detection. This study was conducted to evaluate 
measurements of ibrinogen and hs-CRP on ACS.
METHODS: An analytic observational study with cross 
sectional approach was conducted on patients with Troponin 
I positive. After signing informed consent, anamnesis and 
complete blood count were conducted. Besides that, liver 
function, renal function, and blood glucose tests were 
conducted as well. Samples of selected subjects were 
quantiied with enzyme-linked immunosorbent assay 
(ELISA) for Troponin I, ibrinogen and hs-CRP. Then 
statistical analyses were performed.
Abstract
RESULTS: There were 76 subjects in each ACS and non-
ACS groups. ACS group showed signiicant higher levels 
of both ibrinogen and hs-CRP compared to Non-ACS 
group (p=0.000). Among evaluated risk factors, diabetes 
mellitus (DM) (p=0.003) and hypertension (p=0.000) were 
signiicantly higher in ACS group than in non-ACS group. 
Among evaluated clinical factors, blood glucose (p=0.001) 
and age (p=0.000) were signiicantly higher in ACS group 
than in non-ACS group. Combination of ibrinogen and hs-
CRP measurements showed the highest sensitivity (75.00%), 
speciicity (80.26%), accuracy (77.63%), positive predictive 
value (79.19%) and negative predictive value (76.25%).
CONCLUSION: Since ibrinogen and hs-CRP were 
increased in ACS group and combination of ibrinogen 
and hs-CRP measurements showed the highest sensitivity, 
speciicity, accuracy, positive predictive value and negative 
predictive value, we suggest that combination of ibrinogen 
and hs-CRP measurements could give added value to 
identify ACS.
KEYWORDS: ibrinogen, hs-CRP, biomarker, ACS, acute 
coronary syndrome, atherosclerosis, inlammation
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Introduction
Acute myocardial infarction (AMI) is one of cardiovascular 
diseases (CVDs) with high morbidity and mortality rates. 
American Heart Association estimated that more than 6 
millions Americans have coronary heart disease (CHD) 
and it is estimated that 1 million have myocardial infarction 
attack every year. CHD is also the leading cause of death 
(20%) in United States of America. Indonesian Domestic 
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can be more potential biomarkers for ACS early detection, 
compared to other current biomarkers. This study evaluated 
measurements of ibrinogen and hs-CRP on ACS.(6,15,16)
Study Design and Subjects Recruitment
This study was an analytic observational with cross sectional 
approach to evaluate the diagnostic value of ibrinogen 
and hs-CRP in establishing ACS diagnosis among patients 
hospitalized in Dr. Saiful Anwar Hospital with Troponin I 
positive. Subjects were men and women aged 35 to 80 years 
old with ACS as the case group and without ACS as the 
control group. Subjects with severe infection, liver function 
disorder, renal function disorder, and malignancy were 
eliminated from this study.  This research was carried out 
on patients from emergency department and cardiovascular 
intensive care unit of Dr. Saiful Anwar Hospital.
Data Collection, Sample Preparation and Enzyme-
linked Immunosorbent Assay (ELISA)
After signing informed consent, proper anamnesis was 
conducted. Then blood sample was collected for complete 
blood count. Besides that, liver function, renal function, 
and blood glucose tests were all conducted. Samples of 
selected subjects were quantiied with enzyme-linked 
immunosorbent assay (ELISA) for Troponin I (Troponin I 
ELISA Kit, Sigma Aldrich, St. Louis, MO, USA), ibrinogen 
(Fibrinogen Human ELISA Kit, Abcam, Cambridge, UK) 
and  hs-CRP (Quantikine® ELISA Human C-Reactive 
Protein/CRP Immunoassay, Minneapolis, MN, USA).
Statistical Analysis
Data was descriptively analyzed to portray the characteristics 
of case and control groups, as well as the information of 
classic risk factors and clinical characteristics. Differences 
of ibrinogen and hs-CRP in both groups were statistically 
examined with independent t-test. Correlation test was 
performed as well. To ind out which biomarker level has 
the highest accuracy to ACS, cut-off point for each level 
and logistic regression were carried out to ind the predicted 
probability value for ibrinogen combination data and hs-
CRP as the basis of cut-off value determination through 
receiver operating curve (ROC). The sensitivity, speciicity, 
likelihood ratio and predictive value were further counted 
by using ibrinogen and hs-CRP, either separated or 
combination of both.
Methods
Health Survey / Survei Kesehatan Rumah Tangga (SKRT) 
performed in 1992, showed that people over 40 years 
old have CVD-caused mortality at the irst rank (16%). 
Similar survey held in Java and Bali in 1995 pointed that 
CVD-caused mortality was at the irst rank as well, and 
its percentage (25%) was higher compared to the data 
from SKRT in 1992. Among CVD, CHD had the highest 
morbidity rate (30-36.1%).(1)
 High AMI morbidity and mortality rates suggested the 
necessity of an earlier diagnosis for immediate treatment 
and death prevention. Acute coronary syndrome (ACS) is a 
heart emergency situation of which clinical manifestation is 
chest discomfort or any other symptoms due to myocardial 
infarction. ACS consists of unstable angina pectoris. AMI 
is divided into ST segment elevation myocardial infarction 
(STEMI) and non STEMI (NSTEMI).(2,3)
 To date, ACS diagnosis was determined by cardiac 
enzyme Troponin I or T measurements that could be 
detected started from 4 to 8 hours after the onset of chest 
pain. Troponin reached its peak level at 12-36 hours after the 
onset, then kept increasing for 7-9 days. False positive was 
commonly found in patients with chronic kidney disease 
(CKD) and those who were undergoing dialysis. Another 
biomarker for ACS is creatine kinase muscle brain that 
could be detected 4-6 hours after AMI onset and reaches its 
peak level within 18-24 hours then back to its normal value 
in 2-3 days. This biomarker is not quite speciic for cardiac 
muscle and false positive was sometimes found in patients 
with renal failure.(4,5)
 Fibrinogen and C-reactive protein (CRP) are 
biomarkers that act as acute phase proteins. Fibrinogen 
plays role in coagulation process, blood viscosity, and 
platelet aggregation, while high sensitivity CRP (hs-CRP) 
works in inlammation process. Many studies have reported 
ibrinogen and hs-CRP used as an early stage detecting 
biomarker and prognosis decision for CHD.(6,7) If these 
two biomarkers were detected earlier in ACS patients, 
the proper treatment can be immediately given, and more 
extensive myocardial muscle damage can be prevented.
(8,9) Currently, in Indonesian hospitals, particularly in 
Dr. Saiful Anwar Hospital in Malang, the ibrinogen and 
hs-CRP measurements have not yet been considered as a 
routine procedure for ACS patients. Enzyme evaluation 
that is usually performed tends to relect that there has 
been cardiac muscle damages.(2,10,11) Meanwhile, 
the role of inlammatory marker in ACS diagnosis has 
been reported.(12-14) Fibrinogen and hs-CRP  roles in 
inlammation process indicate that ibrinogen and hs-CRP 
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There were 76 subjects in each group, hence there were 
totally 152 subjects of men and women. The mean of age 
was 57.5 years old. Comparison of ibrinogen and hs-CRP 
levels between ACS and non-ACS groups is shown in Table 
1. ACS group had higher levels of both ibrinogen and hs-
CRP compared to Non-ACS group. Independent t-tests for 
ibrinogen and hs-CRP levels between ACS and non-ACS 
group were signiicant (p=0.000, p<0.05).
Results
Meanwhile, systolic and diastolic BP did not have signiicant 
differences between ACS and Non-ACS groups (p>0.05).
 Cut-off for hs-CRP was set at 3.05 mg/L, while cut-off 
for ibrinogen was 4.25 g/L. More subjects with higher hs-
CRP level (hs-CRP≥3.05 mg/L) were found in ACS group 
(69.7%) (Table 4). More subjects with higher ibrinogen 
level (Fibrinogen ≥ 4.25g/L) were found in ACS group as 
well (72.4%). When hs-CRP cut-off was combined with 
ibrinogen cut-off, more subjects with higher hs-CRP and 
ibrinogen levels were found in ACS group (80.3%).
Non ACS 
(Mean ± SD)
ACS 
(Mean ±SD)
Fibrinogen (g/L) 3.78 ± 1.38 5.08 ± 1.56 0.000
hs-CRP (mg/L) 1.95 ± 1.25 4.04 ± 1.94 0.000
p value*
Group
Biomarker
Table 1. The Comparison of Fibrinogen and hs-CRP Levels 
between ACS and Non-ACS Groups.
*: Independent t-test
n % n %
Cigarette Smoking 27 35.5 35 46.1 0.248
DM 11 14.5 28 36.8 0.003*
Hypertension 11 14.5 37 48.7 0.000*
ACS Family History 0 0 4 5.3 0.120
p valueRisk Factor Non ACS (n=76) ACS  (n=76)
Group
Table 2. Characteristics of Classic Risk Factor in ACS and Non-ACS Groups.
*: Pearson Correlation Test, signiicant (p<0.05)
Discussion
 Characteristics of classic risk factor in ACS and 
non-ACS groups are shown in Table 2. The evaluated risk 
factors were cigarette smoking, diabetes mellitus (DM), 
history of hypertension and ACS family history. DM was 
signiicantly higher in the ACS group than in non-ACS 
group. Hypertension was also found signiicantly higher 
in ACS group. Meanwhile, cigarette smoking behavior 
and ACS family history were also higher in ACS group, 
however the values were not signiicant (p>0.05).
 Clinical characteristics in ACS and Non-ACS groups 
are shown in Table 3. The evaluated clinical factors were 
systolic blood pressure (BP), diastolic BP, blood glucose 
and age. Not all clinical characteristics had signiicant 
differences between those two groups. The signiicant 
differences were found in blood glucose and age (p<0.05). 
 In combination, ibrinogen and hs-CRP showed the 
highest sensitivity (75.00%) (Figure 5). The same results 
were also found in speciicity (80.26%), accuracy (77.63%), 
positive predictive value (PPV) (79.17%), and negative 
predictive value (NPV) (76.25%).
Our current results shows that detection of both ibrinogen and 
hs-CRP could provide high sensitivity, speciicity, accuracy, 
PPV and NPV results for ACS detection. Since ibrinogen 
and hs-CRP are related with ACS pathophysiology in early 
stage, these biomarkers could be useful for early detection 
of ACS.(17-19) Troponin I detection has higher sensitivity 
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and speciicity than ibrinogen and hs-CRP. However, 
when Troponin I is detected, it will be ACS late stage, the 
cardiac muscle has undergone necrosis or irreversible death. 
Meanwhile ibrinogen and hs-CRP could be detected earlier, 
therefore, it could support early ACS treatment.(9,17)
 Elevated inlammatory markers relect acute phase 
response. An epidemiologic study has shown that levels of 
several inlammatory markers elevated few years prior to 
ACS manifestation.(9,17) Increased levels of ibrinogen and 
hs-CRP in ACS without myocardial infarction correlated 
to the extent and severity of atherosclerosis, while CRP 
level in AMI correlated to the extent of tissue damage. 
Various researches stated that inlammation is an integral 
Non ACS 
(Mean ± SD)
ACS 
(Mean ±SD)
Systolic BP 126.88±111.30 132.33±29.25 0.065
Diastolic BP 81.30±8.32 78.19±16.84 0.332
Blood Glucose 149.28±90.5 189.83±120.13 0.001*
Age 50.04±8.77 59.46±11.74 0.000*
Clinical Factor
Group
p value*
Table 3. Clinical Characteristics in ACS and Non-ACS Groups.
*: Pearson Correlation Test, signiicant (p<0.05)
n % n %
hs-CRP<3.05 mg/L 54 71.1 23 30.3
hs-CRP 3.05 mg/L 22 29 53 69.7
Fibrinogen< 4.25g/L 55 72.4 21 27.6
Fibrinogen  4.25g/L 21 27.6 55 72.4
hs-CRP<3.05 mg/L and 
Fibrinogen <0.480
57 75 15 19.7
hs-CRP 3.05 mg/L and 
Fibrinogen 0.480
19 25 61 80.3
Biomarker & Cut-Off
Group
Non ACS (n=76) ACS  (n=76)
Table 4. Distribution of hs-CRP and Fibrinogen Level, Based on Cut-off 
Point, in ACS and Non-ACS Groups.
part of ACS. CRP is detected in damaged blood vessel or 
myocardium, and involves in inlammation process and 
thrombosis through complement activity. CRP is also 
directly related to tissue factor expression over monocyte 
surface.(3,20)
 Fibrinogen and CRP levels are correlated to several 
classic risk factors like obesity, cigarette smoking, blood 
pressure and blood glucose. Healthy people, whose parents 
have AMI or ACS, can have higher CRP level compared 
to those without AMI family history. Higher ibrinogen and 
hs-CRP levels are reported more in subjects with multiple 
classic risk factors than in those with single classic risk 
factor.(20,21) Among patients with stable and unstable 
Biomarker
Sensitivity 
(%)
Specificity 
(%)
Accuracy 
(%)
PPV 
(%)
NPV 
(%)
hs-CRP 71.05 69.74 70.39 70.13 70.67
Fibrinogen 72.37 72.37 72.37 72.37 72.37
Fibrinogen & hs-CRP 75.00 80.26 77.63 79.17 76.25
Table 5. Predicted Probability of Test Result.
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angina pectoris, it has been proven that ibrinogen and CRP 
can be the predictor of future AMI incidence and heart 
disease-caused death.(9)
 Response-to-injury hypothesis states that 
atherosclerosis is an inlammation disease. It is marked by 
the presence of inlammation process, endothelial cells and 
smooth muscle cells, release of cytokine and growth factor, 
complement activation and deposition, as well as elevated 
plasma protein level which is called acute phase reactant.
(4,5) Inlammation process that involves macrophage, 
lymphocyte, proteinase, and cytokine activations, promotes 
the thrombosis plaque rupture.(6,9) The inlammatory cells 
are responsible for plaque destabilization by changing 
anti-adhesive and anti-coagulant into pro-coagulant 
resulting tissue factor in monocyte to cause plaque rupture. 
Therefore, evident of leukocytosis and elevated CRP level 
indicate AMI. In 15% of AMI patients, CRP elevation is 
reported although Troponin T remains negative. Haidari, 
et al. investigated the correlation between serum CRP and 
CHD with angiography in 450 individuals. The result shows 
that serum CRP was higher in individual with CHD than in 
control group (2.14 mg/L vs. 1.45 mg/L) and the correlation 
indicated that there was inlammatory process in CHD.(9)
 Previous studies demonstrate that ibrinogen could 
be detected in the areas of connective tissue, thrombus 
and cholesterol crystal loss, hence, elevated ibrinogen 
correlates to the degree of atherosclerosis. Fibrinogen level 
elevates signiicantly in most ACS patients, observed among 
49 patients with stable angina and positive Troponin I level 
vs. stable angina with negative Troponin I level (3.87±1.2 
vs. 3.26±0.65, p=0.02). Signiicant correlation between 
ibrinogen and Troponin I among unstable angina patients, 
was discovered.(12) Ben Khalfallah, et al., reported that 
higher ibrinogen level was found in ACS patients compared 
to healthy individuals (4.7±1.81 g/L vs. 3.93±1.69 g/L, 
p=0.02).(6)
 Our results show that combination of both markers, 
hs-CRP and ibrinogen provided higher speciicity and 
sensitivity. The ibrinogen and hs-CRP are factors those 
synergistically correlated to ACS pathophysiology. The 
hs-CRP inluences through inlammation phase, causing 
endothelial dysfunction and unstable plaques.(21) In 
sequence, ibrinogen takes part to the pathophysiology of 
ACS after plaque ruptured from coronary blood vessel by 
inducing coagulation cascade activation with the formation 
of ibrin ibers as the inal process. In which if the ibers 
bond to platelet, thrombus would eventually formed, thus 
promoting ACS.(5,9,17)
 Since ibrinogen and hs-CRP measurements could 
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